Xilio Therapeutics, Inc.
XLONasdaq
$8.88
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -13.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$53.5M
Net Income (TTM)
-$31.3M
Free Cash Flow (TTM)
-$57.4M
Gross Margin
—
Operating Margin
-79.0%
Net Margin
-58.5%
ROE
-43.1%
ROIC
—
Debt / Equity
—
Net Cash
$150.3M
Return 1Y
-12.5%
Company profile
Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.
- CEO
- René Russo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Massachusetts
- Website
- xiliotx.com
Management & directors
- Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
- Frankenfield Christopher JamesChief Financial Officer
- Luptakova KatarinaCHIEF MEDICAL OFFICER
- Russo RenePRESIDENT AND CEO
Roles derived from SEC Form 4 filings.
Earnings
XLO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.6M↑ +331.7%
Diluted EPS-$0.58↓ -76.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $6.3M | $43.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$54.6M | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M |
| Net income | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Diluted EPS | -$105.42 | -$13.52 | -$3.22 | -$2.78 | -$15.24 | -$4.19 |
| Operating cash flow | -$36.1M | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$5.0M |
| Free cash flow | -$38.3M | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -954.9% | -95.9% |
| Net margin | — | — | — | — | -918.0% | -80.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.3M | — | $2.9M | $8.1M | $19.1M | $13.7M | $12.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.7M | -$14.8M | -$13.6M | -$13.9M | -$14.4M | -$1.9M | -$11.8M | -$14.1M |
| Net income | -$13.9M | -$14.0M | -$13.1M | -$13.3M | -$15.8M | -$16.3M | $10.4M | -$9.5M |
| Diluted EPS | -$0.24 | -$0.22 | -$14.16 | -$2.49 | -$0.16 | -$0.11 | -$1.43 | -$0.58 |
| Operating cash flow | $20.0M | -$13.7M | -$14.2M | $29.0M | -$14.5M | -$17.5M | -$2.0M | -$22.3M |
| Free cash flow | — | -$13.7M | — | $29.0M | -$14.9M | -$17.5M | -$2.1M | -$22.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -623.8% | -652.3% | — | -472.7% | -177.7% | -10.1% | -86.5% | -111.6% |
| Net margin | -590.8% | -619.5% | — | -452.7% | -196.0% | -85.4% | 75.7% | -75.3% |
Company news
Jun 29, 2026
May 12, 2026
- 69d agoXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimatesfinance.yahoo.com
- 69d agoOpus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimatesfinance.yahoo.com
- 69d agoXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updatesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Buy | 5,000 | $8.79 | $43,950.00 | filing |
| 2026-01-02 | Frankenfield Christopher James· Chief Financial Officer | Sale | 7,030 | $0.64 | $4,521.70 | filing |
| 2026-01-02 | Brennan Kevin M.· SVP, FINANCE AND ACCOUNTING | Sale | 1,826 | $0.64 | $1,174.48 | filing |
| 2026-01-01 | Russo Rene· PRESIDENT AND CEO | Option exercise | 44,250 | — | — | filing |
| 2026-01-01 | Frankenfield Christopher James· Chief Financial Officer | Option exercise | 19,375 | — | — | filing |
| 2026-01-01 | Luptakova Katarina· CHIEF MEDICAL OFFICER | Option exercise | 16,625 | — | — | filing |
| 2026-01-01 | Brennan Kevin M.· SVP, FINANCE AND ACCOUNTING | Option exercise | 5,000 | — | — | filing |
| 2025-06-17 | Shannon James Samuel | Buy | 25,000 | $0.69 | $17,215.00 | filing |
| 2025-06-16 | Shannon James Samuel | Buy | 45,000 | $0.69 | $30,870.00 | filing |
| 2025-06-16 | Russo Rene· PRESIDENT AND CEO | Buy | 36,289 | $0.68 | $24,680.15 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.